21 assets in Adrenal Cortex Carcinoma

Therapeutic assets addressing Adrenal Cortex Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Adrenal Cortex Carcinoma	Anusha Kalbasi	P2	B (60)
Nivolumab Adrenal Cortex Carcinoma	Dana-Farber Cancer Institute	P2	B (60)
Pembrolizumab Adrenal Cortex Carcinoma	Corcept Therapeutics	P2	B (60)
Cabozantinib Adrenal Cortex Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Dexasone Adrenal Cortex Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Dostarlimab Adrenal Cortex Carcinoma	UNICANCER	P2	CCC (53)
Floxuridine Adrenal Cortex Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Adrenal Cortex Carcinoma	Dana-Farber Cancer Institute	P2	CCC (53)
pds01adc Adrenal Cortex Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Rain-32 Adrenal Cortex Carcinoma	Rain Oncology Inc	P2	CCC (53)
Olaparib Adrenal Cortex Carcinoma	Fundación de investigación HM	P1/2	CCC (48)
Oxodotreotide Adrenal Cortex Carcinoma	Fundación de investigación HM	P1/2	CCC (48)
Autologous Anti-Cd19 Car-Expressing T Lymphocytes Adrenal Cortex Carcinoma	Anusha Kalbasi	P1	CC (43)
b7-h3 car t cells Adrenal Cortex Carcinoma	St. Jude Children's Research Hospital	P1	CC (43)
Fludarabine Adrenal Cortex Carcinoma	Anusha Kalbasi	P1	CC (43)
Fludeoxyglucose Adrenal Cortex Carcinoma	Anusha Kalbasi	P1	CC (43)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells Adrenal Cortex Carcinoma	Anusha Kalbasi	P1	CC (43)
Mesna Adrenal Cortex Carcinoma	St. Jude Children's Research Hospital	P1	CC (43)
Mrna-0523-L001 Adrenal Cortex Carcinoma	Shanghai Jiao Tong University School of Medicine	N/A	D (30)
ds9051b Adrenal Cortex Carcinoma	Daiichi Sankyo	P1	NR ()
Ivocizumab Adrenal Cortex Carcinoma	Fudan University	P2	NR ()